<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03767478</url>
  </required_header>
  <id_info>
    <org_study_id>P63190</org_study_id>
    <secondary_id>IRAS ID</secondary_id>
    <secondary_id>NRES REC ID</secondary_id>
    <nct_id>NCT03767478</nct_id>
  </id_info>
  <brief_title>Neuromuscular Electrical Stimulation For The Treatment of Diabetic Peripheral Neuropathy</brief_title>
  <acronym>NMES for DPN</acronym>
  <official_title>Neuromuscular Electrical Stimulation For The Treatment of Diabetic Peripheral Neuropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imperial College London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Actegy Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Imperial College London</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Diabetic peripheral neuropathy is a disabling condition, which is characterized by numbness,
      hypersensitivity or pain in the extremities. The cause is thought to be due to damaged nerves
      due to poor circulation. A new therapy option has recently become available to increase blood
      flow in the legs. The aim of this study is to assess if it is possible to improve or resolve
      symptoms of diabetic peripheral neuropathy in patients by improving the blood supply to the
      legs.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 27, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in nerve conduction parameters</measure>
    <time_frame>6 months</time_frame>
    <description>Two component, single outcome - Any Improvement in nerve conduction parameters compared to baseline of the tested sensory nerves at 6 months. Change in conduction velocities compared to baseline of the peroneal motor nerve</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Balance Symptoms</measure>
    <time_frame>6 months</time_frame>
    <description>Berg Balance Scale Questionnaire is a 14-item disease specific questionnaire (scoring up to 56) assessing elements of balance, with each element scoring 0-4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Questionnaires - EuroQol 5 Domain Quality of Life Questionnaire</measure>
    <time_frame>6 months</time_frame>
    <description>EuroQol 5 Domain Quality of Life (EQ-5D QOL) questionnaire will provide assessment of the participants quality of life (EQ-5D QOL from 0-1).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compliance to treatment</measure>
    <time_frame>6 months</time_frame>
    <description>Patient Diary</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arterial Blood Flow</measure>
    <time_frame>6 months</time_frame>
    <description>Arterial Blood flow assessed by ultrasound, utilising standard Haemodynamics assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuropathy symptoms</measure>
    <time_frame>6 months</time_frame>
    <description>NTSS-6 Questionnaire is a 6 item questionnaire, scoring a maximum of 3.66 per item with a maximum score of 21.96. This grades neuropathy symptomatology.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daily Pain Score</measure>
    <time_frame>6 months</time_frame>
    <description>This will be assessed using a Visual Analogue Scale (VAS) to assess individual pain scores.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diabetic Neuropathy</measure>
    <time_frame>6 months</time_frame>
    <description>Michigan Neuropathy Screening Instrument is a patient (15 questions) and clinician (5 questions) completed questionnaire that allows assessment of neuropathy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Questionnaires - EuroQol Visual Analogue Scale</measure>
    <time_frame>6 months</time_frame>
    <description>Euroqol Visual Analogue Scale (EQ5D VAS) will provide assessment of the participants quality of life (EQ5D VAS from 0-100).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">141</enrollment>
  <condition>Diabetic Neuropathies</condition>
  <arm_group>
    <arm_group_label>Group A - Sham Comparator</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>12 Months of Sham Comparator (Sham Revitive Medic Neuromuscular Stimulation Device).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B1 - Active Comparator &amp; Active Comparator</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Active Comparator for 6 months (Revitive Medic Neuromuscular Stimulation Device). Then randomisation into active comparator (Revitive Medic Neuromuscular Stimulation Device) for further 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B2 - Active Comparator &amp; Sham Comparator</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Active Comparator for 6 months (Revitive Medic Neuromuscular Stimulation Device). Then randomisation into sham comparator (Sham Revitive Medic Neuromuscular Stimulation Device) for further 6 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Revitive Medic (Actegy Ltd)</intervention_name>
    <description>Twice daily use (2 x 30 minute sessions) of the footplate neuromuscular stimulation device (Revitive Medic).</description>
    <arm_group_label>Group A - Sham Comparator</arm_group_label>
    <arm_group_label>Group B1 - Active Comparator &amp; Active Comparator</arm_group_label>
    <arm_group_label>Group B2 - Active Comparator &amp; Sham Comparator</arm_group_label>
    <other_name>Footplate Neuromuscular Stimulation Device</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of diabetes mellitus on best medical therapy.

          -  Diagnosis of diabetic peripheral neuropathy base on a validated screening
             questionnaire (Michigan Neuropathy Screening Instrument) score of &gt;6 and nerve
             conduction study

          -  Aged 18+.

          -  Capacity to provide informed consent

        Exclusion Criteria:

          -  Lacks capacity to provide informed consent.

          -  Pregnant. Participants must be of non-childbearing age potential or using adequate
             contraception for the duration of the study period and have a negative urine pregnancy
             test

          -  Has a cardiac pacemaker, or other defibrillator device.

          -  Has current foot ulceration.

          -  Has other cause of peripheral neuropathy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alun H Davies, MA DM DSC FRCS FEBVS</last_name>
    <role>Study Chair</role>
    <affiliation>Imperial College London</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tristan R A Lane, MBBS BSc FRCS PhD</last_name>
    <phone>02033117317</phone>
    <email>tristan.lane@imperial.ac.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Imperial College London</name>
      <address>
        <city>London</city>
        <zip>W6 8RF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tristan R Lane, PhD FRCS</last_name>
      <email>tristan.lane@imperial.ac.uk</email>
    </contact>
    <contact_backup>
      <last_name>Karen Dhillon</last_name>
      <email>karen.dhillon@nhs.net</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>November 27, 2018</study_first_submitted>
  <study_first_submitted_qc>December 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 6, 2018</study_first_posted>
  <last_update_submitted>February 26, 2019</last_update_submitted>
  <last_update_submitted_qc>February 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 27, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>neuromuscular stimulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Nervous System Diseases</mesh_term>
    <mesh_term>Diabetic Neuropathies</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Available on request.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

